Med Lett Drugs Ther. 2006 May 8;48(1234):37.
Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a better choice than tamoxifen (Nolvadex, and others) for prevention of breast cancer in high-risk postmenopausal women.
一项新研究的初步结果尚未发表，但在国立癌症研究所的新闻稿中有所报道，并在大众媒体上广泛传播。该结果表明，对于预防高危绝经后女性的乳腺癌，雷洛昔芬（易维特）可能是比他莫昔芬（诺瓦得士等）更好的选择。
